SAR156597

DRUG3 trials

Sponsors

Sanofi

Conditions

Idiopathic Pulmonary FibrosisSystemic Sclerosis

Phase 1

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

CompletedNCT01529853

SanofiIdiopathic Pulmonary Fibrosis

Start: 2012-01-31End: 2013-10-31Updated: 2016-02-15

Phase 2

Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis

CompletedNCT02345070

SanofiIdiopathic Pulmonary Fibrosis

Start: 2015-05-01End: 2017-08-14Updated: 2022-03-24

Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis

CompletedNCT02921971

SanofiSystemic Sclerosis

Start: 2016-12-21End: 2019-04-01Updated: 2022-03-21

Related Papers

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.

2020-09-2276 citations

SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772)

European Respiratory Journal2018-10-1894 citations

Late Breaking Abstract - Prevalence and clinical significance of antinuclear antibody (ANA) in IPF: analysis from ESTAIR study

2018-09-15